We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Parker Laboratories

Manufactures medical ultrasound and electromedical contact media, including gels, solid gels, lotions and pads read more Featured Products: More products

Download Mobile App




Parker Labs in Alliance for Ultrasound Probe Disinfectant

By MedImaging International staff writers
Posted on 19 Jul 2022
Print article
Image: Tristel Duo ULT offers high-level disinfection for all parts of an ultrasound transducer (Photo courtesy of Tristel)
Image: Tristel Duo ULT offers high-level disinfection for all parts of an ultrasound transducer (Photo courtesy of Tristel)

Parker Laboratories Inc. (Fairfield, NJ, USA) and Tristel plc (Newmarket, UK) have entered into a commercial partnership in which Tristel will manufacture and distribute its high-level ultrasound probe disinfectants.

Tristel is a UK-based manufacturer of infection prevention products. Ultrasound probe disinfection is one of Tristel's most important areas of focus within the hospital infection prevention market, accounting for approximately 40% of the company's global revenues. Parker is a leading manufacturer in the US market for the conductive gels and sheaths that are used in all ultrasound procedures, with a nationwide distribution network.

Tristel has submitted its De Novo request for approval to the US FDA for Tristel Duo ULT, a high-level disinfectant foam that can be used on ultrasound probes used for intra-cavitary and skin surface diagnostic procedures. To Tristel’s knowledge, Tristel Duo ULT is the first disinfectant to make a De Novo request to the FDA, reflecting the novelty of the product. Duo ULT is widely used throughout Europe, the Middle East, Asia, and Australasia. During the company's current financial year, the product will have been used in over eight million disinfection procedures of ultrasound probes worldwide.

The FDA's De Novo review and approval process stipulates a 150-day decision timeframe. Additional data requests are commonplace, and the FDA website states that the average duration for review and approval is approximately 11 months. Tristel is also proceeding with the state registration of another version of Duo which has been approved by the US EPA for the disinfection of general medical surfaces. The company has received 24 state approvals and anticipates that all others will have been received by the end of 2022. Tristel will manufacture and distribute both Duo products via its commercial partnership with Parker.

"After five years of testing and data generation we are very pleased to have finally submitted our De Novo request for approval to the FDA. We have made an investment of GBP 2.8 million in the project which has all been expensed," said Paul Swinney, Chief Executive of Tristel plc. "The United States is the largest ultrasound market in the world and our competitors will be the same as those we compete with in all our other markets worldwide. To our knowledge no new high-level disinfectant has been approved by the FDA and introduced into the United States since 2011, other than variants of previously approved products. Duo ULT is recognized as a leading high-level disinfectant throughout the rest of the world, and our entry into the United States market will be a significant inflection point for the company."

Related Links:
Parker Laboratories Inc.
Tristel plc

New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Frontal Apron
601 - Frontal Apron
New
Fixed X-Ray System (RAD)
Allengers 325 - 525
New
Gold Member
X-Ray QA Meter
T3 RG Pro

Print article
Radcal

Channels

MRI

view channel
Image: MRI-linac allows clinicians to see what’s going on in the brain for the first time (Photo courtesy of Sylvester Comprehensive Cancer Center)

MRI Provides Early Warning System for Glioblastoma Growth

A new study has demonstrated the potential of combining imaging with radiation to shape glioblastoma treatment in real time. The research is the first to quantify tumor changes in glioblastoma patients... Read more

Ultrasound

view channel
Image: Disease captured by the hand-held 3D photoacoustic scanner (Photo courtesy of Dr. Nam Huynh)

Medical Imaging Breakthrough to Revolutionize Cancer and Arthritis Diagnosis

Photoacoustic tomography (PAT) imaging uses laser-generated ultrasound waves to detect subtle changes in small veins and arteries, typically less than a millimeter in size and up to 15mm deep in human tissues.... Read more

Nuclear Medicine

view channel
Image: A new biomarker makes it easier to distinguish between Alzheimer’s and primary tauopathy (Photo courtesy of Shutterstock)

Diagnostic Algorithm Distinguishes Between Alzheimer’s and Primary Tauopathy Using PET Scans

Patients often present at university hospitals with diseases so rare and specific that they are scarcely recognized by physicians in private practice. Primary 4-repeat tauopathies are a notable example.... Read more

General/Advanced Imaging

view channel
Image: A kidney showing positive [89Zr]Zr-girentuximab PET and histologically confirmed clear-cell renal cell carcinoma (Photo courtesy of Dr. Brian Shuch/UCLA Health)

Non-Invasive Imaging Technique Accurately Detects Aggressive Kidney Cancer

Kidney cancers, known as renal cell carcinomas, account for 90% of solid kidney tumors, with over 81,000 new cases diagnosed annually in the United States. Among the various types, clear-cell renal cell... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.